4/A: Establishment Labs Holdings Inc.: Executive Receives Stock Units and Options

Samuel Ross Mansbach, GC & Chief HR Officer of Establishment Labs Holdings Inc., reports the acquisition of stock units and options under the company's 2018 Equity Incentive Plan.

Summary

• On March 6, 2024, Samuel Ross Mansbach, GC & Chief HR Officer of Establishment Labs Holdings Inc., acquired 5,406 common shares and 7,691 stock options.
• The common shares were awarded as stock units under the Issuer's 2018 Equity Incentive Plan.
• One-fourth of the shares and options will vest on March 6, 2025, and annually thereafter, contingent upon continued service.
• Following the transaction, Mansbach directly owns 7,691 derivative securities and 8,014 common shares.
• This Form 4/A is an amendment to the original filing made on March 19, 2024.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, indicating a stable and incentivized management structure. The sentiment is neutral to slightly positive.

Positives

• The vesting schedule incentivizes continued service by the GC & Chief HR Officer.
• The acquisition of stock units aligns the executive's interests with those of the shareholders.

Risks

• The vesting of the stock units and options is contingent upon continued service, creating a potential risk if the executive leaves the company before full vesting.

Future Outlook

The executive's compensation is tied to the company's performance through equity-based incentives, aligning their interests with shareholders.

Industry Context

Equity-based compensation is a common practice in the industry to attract and retain key personnel and align their interests with those of the shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in publicly traded companies, particularly in growth-oriented sectors like medical technology.
• Vesting schedules, such as the four-year vesting period described, are typical to ensure long-term commitment from executives.
• Comparing the size of the grant to similar companies in the medical aesthetics industry would provide further context on the competitiveness of the compensation package.

Stakeholder Impact

• The equity-based compensation aligns the executive's interests with those of the shareholders, potentially leading to increased shareholder value.
• The vesting schedule incentivizes the executive to remain with the company, providing stability for employees and other stakeholders.

Next Steps

• Continued monitoring of insider transactions and beneficial ownership changes.
• Tracking the vesting of the stock units and options over the next four years.

Key Dates